For the quarter ending 2025-09-30, SNSE made $5,140K in revenue. -$4,569K in net income. Net profit margin of -88.89%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 2,536 | 2,533 | ||
| General and administrative | 2,315 | 2,673 | ||
| Total operating expenses | 4,851 | 5,206 | ||
| Loss from operations | -4,851 | -5,206 | ||
| Interest income | 289 | 321 | ||
| Interest expense | 6 | 10 | ||
| Loss on asset disposal | -1 | -40 | ||
| Other expense, net | 0 | -1 | ||
| Net loss | -4,569 | -4,936 | ||
| Earnings per share, basic | -3.62 | -3.91 | ||
| Earnings per share, diluted, total | -3.62 | -3.91 | ||
| Weighted average number of shares outstanding, basic, total | 1,261,290 | 1,260,867 | ||
| Weighted average number of shares outstanding, diluted, total | 1,261,290 | 1,260,867 | ||
Sensei Biotherapeutics, Inc. (SNSE)
Sensei Biotherapeutics, Inc. (SNSE)